Curis Inc (CRIS) USD0.01

Sell:$2.71Buy:$2.85$0.21 (7.98%)

Prices delayed by at least 15 minutes
Sell:$2.71
Buy:$2.85
Change:$0.21 (7.98%)
Deal now
Prices delayed by at least 15 minutes
Sell:$2.71
Buy:$2.85
Change:$0.21 (7.98%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.

Key people

James E. Dentzer
President, Chief Executive Officer, Director
Diantha Duvall
Chief Financial Officer
Jonathan Zung
Chief Development Officer
Martyn D. Greenacre
Independent Chairman of the Board
Anne Borgman
Independent Director
John A. Hohneker
Independent Director
Kenneth I. Kaitin
Independent Director
Marc Rubin
Independent Director
Click to see more

Key facts

  • EPIC
    CRIS
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US2312693094
  • Market cap
    $24.05m
  • Employees
    48
  • Shares in issue
    8.47m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.